Home/Pipeline/Spinal Disc Regeneration

Spinal Disc Regeneration

Degenerative Disc Disease

ResearchR&D

Key Facts

Indication
Degenerative Disc Disease
Phase
Research
Status
R&D
Company

About PUR Biologics

PUR Biologics is a clinical-stage biotechnology company developing next-generation biologic products for the multi-billion-dollar orthopedic and spinal regenerative medicine markets. Founded in 2018, the company's strategy is built on a diversified platform of human tissue allografts, synthetic scaffolds, and cellular/amniotic technologies aimed at promoting bone growth, cartilage repair, and disc regeneration. As a key subsidiary of the publicly traded entity HippoFi (ORHB), PUR Biologics aims to commercialize advanced delivery systems like Active Orb and Vital-Mobile while progressing its pipeline toward addressing significant unmet needs in joint preservation and spinal health.

View full company profile

Therapeutic Areas

Other Degenerative Disc Disease Drugs

DrugCompanyPhase
Intervertebral disk implantBiovaturePre-clinical
AMFX-100Amphix BioDiscovery/Preclinical